[1] J. A. Pineda, M. R. Gomez, F. D. Garcia, et al., “HIV Coinfection Shortens the Survival of Patients with Hepatitis C Virus Related Decompensated Cirrhosis,” Hepatology, Vol. 41, No. 4, 2005, pp. 779-789. doi:10.1002/hep.20626
[2] M. Puoti, R. Rossotti, A. Garlaschelli and R. Bruno, “Hepatocellular Carcinoma in HIV Hepatitis C Virus,” Current Opinion in HIV and AIDS, Vol. 6, No. 1, 2011, pp. 534-538. doi:10.1097/COH.0b013e32834bd2b7
[3] E. Strauss, “Usefulness of Liver Biopsy in Chronic Hepatitis C,” Annals of Hepatology, Vol. 9, 2010, pp. 39-42.
[4] P. Calès, P. Halfon, D. Batisse, et al., “Comparison of Liver Fibrosis Blood Tests Developed for HCV with New Specific Tests in HIV/HCV Co-Infection,” Journal of Hepatology, Vol. 53, No. 2, 2010, pp. 238-244.
[5] M. Sánchez-Conde, M. L. Montes-Ramírez, P. Miralles, et al., “Comparison of Transient Elastography and Liver Biopsy for the Assessment of Liver Fibrosis in HIV/ Hepatitis C Virus-Coinfected Patients and Correlation with Noninvasive Serum Markers,” Journal of Viral Hepatitis, Vol. 17, No. 4, 2010, pp. 280-286. doi:10.1111/j.1365-2893.2009.01180.x
[6] E. Garlassi, P. Ventura, P. Beretta, et al., “Hepato Cellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard,” Infection, Vol. 38, Suppl. 1, 2010, pp. 82-182.
[7] K. Prestini, L. Biasi, M. Mendeni, et al., “Incidence and Predictors of Hepatocellular Carcinoma (HCC) in Cirrhotics Living with HIV (Abstract),” 5th International HIV and Hepatitis Workshop, Lisbon, 4-6 June 2009.
[8] N. Qurishi, C. Kreuzberg, G. Luchters, et al., “Effect of Antiretroviral Therapy on Liver Related Mortality in Patients with HIV and Hepatitis C Virus Coinfection,” Lancet, Vol. 362, No. 9397, 2003, pp. 1708-1713. doi:10.1016/S0140-6736(03)14844-1
[9] J. A. Pineda, J. A. García-García, M. Aguilar-Guisado, et al., “Clinical Progression of Hepatitis C Virus-Related Chronic Liver Disease in Human Immunodeficiency Virus-Infected Patients Undergoing Highly Active Antiretroviral Therapy,” Hepatology, Vol. 46, No. 3, 2007, pp. 622-630.
[10] M. Lopez-Dieguez, M. L. Montes, J. F. Pascual Pereja, et al., “The Natural History of Liver Cirrhosis in HIV-Hepatitis C Virus-Coinfected Patients,” AIDS, Vol. 25, No. 7, 2011, pp. 899-904. doi:10.1097/QAD.0b013e3283454174
[11] M. Saves, S. Vandentorren, V. Daucourt, et al., “Severe Hepatic Cytolysis: Incidence and Risk Factors in Patients Treated by Antiretroviral Combinations. Aquitaine Cohort, France, 1996-1998,” AIDS, Vol. 13, No. 17, 1999, pp. F115-F121. doi:10.1097/00002030-199912030-00002
[12] M. V. Ragni, B. Eghttesad, K. W. Schlesinger, et al., “Pretransplant Survival Is Shorter in HIV-Positive than HIV-Negative Subjects with End-Stage Liver Disease,” Liver Transplant, Vol. 11, No. 11, 2005, pp. 1425-1430. doi:10.1002/lt.20534
[13] Y. Sugawara, S. Tamura and N. Kokudo, “Liver Transplantation in HCV/HIV Positive Patients,” World Journal of Gastrointestinal Surgery, Vol. 3, No. 2, 2011, pp. 21-28. doi:10.4240/wjgs.v3.i2.21
[14] M. V. Ragni, S. H. Belle, K. Im, et al., “Survival of Human Immunodeficiency Virus Infected Liver Transplant Recipients,” The Journal of Infectious Diseases, Vol. 188, No. 10, 2003, pp. 1412-1420. doi:10.1086/379254
[15] G. W. Neff, A. Bonham, A. G. Tzakis, et al., “Orthtopic Liver Transplantation in Patients with Human Immunodeficiency Virus and End-Stage Liver Disease,” Liver Transplant, Vol. 9, No. 3, 2003, pp. 239-247. doi:10.1053/jlts.2003.50054
[16] M. E. de Vera, I. Dvorchik, K. Tom, et al., “Survival of Liver Transplant Patients Coinfected with HIV and HCV Is Adversely Impacted by Recurrent Hepatitis C,” American Journal of Transplantation, Vol. 6, No. 12, 2006, pp. 2983-2993. doi:10.1111/j.1600-6143.2006.01546.x
[17] I. Schreibman, J. J. Gaynor, D. Jayaweera, et al., “Outcomes after Orthotopic Liver Transplantation in 15 HIV-Infected Patients,” Transplantation, Vol. 84, No. 6, 2007, pp. 697-705. doi:10.1097/01.tp.0000282873.24648.5b
[18] J. Miro, M. Montejo, L. Castells, et al., “Prognostic Factors of Mortality in HCV/HIV Coinfected Liver Transplant Recipients from the FIPSE OLT-HIV-05-GESIDA 45-05 Cohort Study (2002-2006),” 15th Conference on Retroviruses and Opportunistic, Boston, 3-6 February 2008, p. 177.
[19] A. L. Mindikoglu, A. Regev and L. S. Magder, “Impact of Human Immunodeficiency Virus on Survival after Liver Transplantation: Analysis of United Network for Organ Sharing Database,” Transplantation, Vol. 85, No. 3, 2008, pp. 359-368. doi:10.1097/TP.0b013e3181605fda
[20] J. C. Duclos-Vallee, C. Feray, M. Sebagh, et al., “Survival and Recurrence of Hepatitis C after Liver Transplantation in Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus,” Hepatology, Vol. 47, No. 2, 2008, pp. 407-417. doi:10.1002/hep.21990
[21] K. Marfo and S. Greenstein, “Antiretroviral and Immunosuppressive Drug-Drug Interactions in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients,” Transplantation Proceedings, Vol. 41, No. 9, 2009, pp. 3796-3799. doi:10.1016/j.transproceed.2009.06.186
[22] V. Soriano, M. Puoti, P. Garcia-Gascó, J. K. Rockstroh, Y. Benhamou, P. Barreiro and B. McGovern, “Antiretroviral Drugs and Liver Injury,” AIDS, Vol., 22, No. 1, 2008, pp. 1-13. doi:10.1097/QAD.0b013e3282f0e2fd
[23] I. Maida, S. Babudieri, C. Selva, et al., “Liver Enzyme Elevation in Hepatitis C Virus (HCV)-HIV-Coinfected Patients Prior and after Initiation of CART: Role of HCV Genotypes,” AAIDS Research and Human Retroviruses, Vol. 22, No. 2, 2006, pp. 139-143. doi:10.1089/aid.2006.22.139
[24] M. John, J. Flexman and M. A. H. French, “Hepatitis C Virus-Associated Hepatitis Following Treatment of HIV-Infected Patients with HIV Protease Inhibitors: An ‘Immune Restoration Disease’?” AIDS, Vol. 12, No. 17, 1998, pp. 2289-2293. doi:10.1097/00002030-199817000-00010
[25] M. A. French, N. Lenzo, M. John, et al., “Immune Restoration Disease after the Treatment of Immunodeficient HIV-Infected Patients with Highly Active Antiretroviral Therapy,” HIV Medicine, Vol. 1, No. 2, 2001, pp. 107-115.
[26] I. Ofotokun, S. E. Smithson, C. Lu, et al., “Liver Enzyme Elevation and Immune Reconstitution among Treatment Naive HIV-Infected Patients Instituting Antiretroviral Therapy,” The American Journal of the Medical Sciences, Vol. 334, No. 5, 2007, pp. 334-341. doi:10.1097/MAJ.0b013e31811ec780
[27] S. F. Stone, S. Lee, N. M. Keane, et al., “Association of Increased Hepatitis C Virus (HCV)-Specific IgG and Soluble CD26 Dipeptidyl Peptidase IV Enzyme Activity with Hepatotoxicity after Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-HCV-Coinfected Patients,” The Journal of Infectious Diseases, Vol. 186, No. No. 10, 2002, pp. 1498-1502.
[28] G. Moyle, “Mechanism of HIV and Nucleoside Reverse Transcriptase Inhibitor Injury to Mitochondria,” Antiviral Therapy, Vol. 10, Suppl. 2, 2005, pp. M47-M52.
[29] A. Igoudjil, A. Abbey-Toby, K. Begriche, et al., “High Doses of Stavudine Induce Fat Wasting and Mild Liver Damage without Impairing Mitochon Drial Respiration in Mice,” Antiviral Therapy, Vol. 12, No. 3, 2007, pp. 389-400.
[30] P. Braitstein, A. Palepu, D. Dietrich, et al., “Special Considerations in the Initiation and Management of Antiretroviral Therapy in Individuals Coinfected with HIV and Hepatitis C,” AIDS, Vol. 18, No. 17, 2004, pp. 2221-2234. doi:10.1097/00002030-200411190-00002
[31] Z. S. Lamar and M. Nunez, “Higher Risk of Severe Drug-Induced Liver Injury among Hispanic HIV-Infected Patients after Initiation of Highly Active Antiretroviral Therapy,” journal of the International Association of Providers of AIDS Care (JIAPAC), Vol. 10, No. 3, 2011, pp. 183-186. doi:10.1177/1545109711401411
[32] L. Martin-CarboneroL, M. Nunez, J. Gonzalez-Lahoz and V. Soriano, “Incidence of Liver Injury after Beginning Antiretroviral Therapy with Efavirenz or Nevirapine,” HIV/AIDS Clinical Trials, Vol. 4, No. 2, 2003, pp. 115-120. doi:10.1310/N4VT-3E9U-4BKN-CRPW
[33] F. Vanleth, P. Phanuphak, K. Ruxrungtham, et al., “Comparison of first-Line Antiretroviral Therapy with Regimens including Nevirapine, Efavirenz, or Both Drugs plus Stavudine and Lamivudine: A Randomized Open-Label Trial, the 2NN Study,” Lancet, Vol. 363, No. 9417, 2004, pp. 1253-1263. doi:10.1016/S0140-6736(04)15997-7
[34] B. Clotet, N. Clumeck, C. Katlama, et al., “Safety of Etravirine in HIV-1/Hepatitis B and/or C Virus Co-Infected patients: Pooled 96 Week Results from the Phase III DUET Trials,” Journal of Antimicrobial Chemotherapy, Vol. 65, No. 11, 2010, pp. 2450-2454. doi:10.1093/jac/dkq332
[35] M. Sulkowski, S. Mehta, R. Chaisson, et al., “Hepatotoxicity Associated with Protease Inhibitor-Based Antiretroviral Regimens with or without Concurrent Ritonavir,” AIDS, Vol. 18, No. 17, 2004, pp. 2277-2284. doi:10.1097/00002030-200411190-00008
[36] J. C. Gathe Jr, G. Pierone, P. Piliero, et al., “Efficacy and Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type-1 Infected Patients,” AIDS Research Human Retroviruses, Vol. 23, No. 2, 2007, pp. 216-223. doi:10.1089/aid.2006.0178
[37] K. McKeage, C. M. Perry, S. J. Keam, et al., “Darunavir: A Review of Its Use in the Management of HIV Infection in Adults,” Drugs, Vol. 69, No. 4, 2009, pp. 477-503. doi:10.2165/00003495-200969040-00007
[38] V. Sekar, S Spinosa-Guzman, E. De Paepe, et al., “Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment,” Clinical Pharmacokinetics, Vol. 49, No. 5, 2010, pp. 343-350. doi:10.2165/11530690-000000000-00000
[39] A. Rachilis, Clotet B, J. Baxter, et al., “Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-Infected Patients in POWER 1 and 3,” HIV Clinical Trials, Vol. 8, No. 4, 2007, pp. 213-220. doi:10.1310/hct0804-213
[40] M. Regazzi, P. Villani, R. Gulminetti, et al., “Therapeutic Monitoring and Variability of Atazanavir in HIV-Infected Patients, with and without HCV Coinfection, Receiving Boosted or Unboosted Regimens,” Therapeutic Drug Monitoring, Vol. 33, No. 3, 2011, pp. 303-308.
[41] F. Gatti, P. Nasta, A. Loregian, et al., “Unboosted Fosamprenavir Is Associated with Low Drug Exposure in HIV-1 Infected Patients with Mild Moderate Liver Impairment Resulting from HCV Related Cirrhosis,” Journal of Antimicrobial Chemotherapy, Vol. 63, No. 3, 2009, pp. 575-578. doi:10.1093/jac/dkn525
[42] P. Nasta, F. Gatti, F. Borghi, et al., “Raltegravir He patic Tolerability in Patients with or without HIV/HCV Co-Infection,” Fifth Workshop on HIV and Hepatitis Co-Infection, 19-21 June, 2009, Lisbon, Abs. 38.
[43] J. Macias, K. Neukam, J. Poetilla and J. A. Jribarren (de Los Santos and al for HEPRAL Study Team), “Liver Tolerance of Raltegravir-Containing Antiretroviral Therapy in HIV-Infected Patients with Chronic Hepatitis C,” Journal of Antimicrobial Chemotherapy, Vol. 66, No. 6, 2011, pp. 1346-1350.doi:10.1093/jac/dkr083
[44] M. Genebat, E. Ruiz-Mateos, I. Pulido, A. Gonzalez-Serma, A. Garcia-Perganeda, et al., “Long-term Immunovirogical Effect and Tolerability of a Maraviroc-Containing Regimen in Routine Clinical Practice,” Currrent HIV Research, Vol. 8, No. 6, 2010, pp. 482-486.
[45] S. Abel, J. D. Davis, C. E. Ridgway, et al., “Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of Maraviroc in HIV-Negative Subjects with Mild and Moderate Hepatic Impairment,” Antiviral Therapy, Vol. 14, 2009, pp. 831-837. doi:10.3851/IMP1297
[46] P. Nasta, “Immune Activation, Aging and Gender and Progression of Liver Disease,” Acta Bio-Medica, Vol. 82, No. 2, 2011, pp. 115-123.
[47] F. Bani-Sadr, F. Carrat, P. Bedossa, et al., “Hepatic Steatosis in HIV-HCV Coinfected Patients: Analysis of Risk Factors,” AIDS, Vol. 20, No. 4, 2006, pp. 525-531. doi:10.1097/01.aids.0000210606.63138.f5
[48] B. H. McGovern, “Hepatic Steatosis in HV/HCV-Coinfected Patients: Time to Reevaluate! Gastroenteroogy, Vol. 140, No. 3, 2011, pp. 809-817. doi:10.1053/j.gastro.2011.01.025
[49] P. Halfon, G. Penaranda, F. Carrat, et al., “Influence of Insulin Resistance on Hepatic Fibrosis and Steatosis in HCV Monoinfected Compared with HIV-HCV Co-Infected Patients,” Alimentary Pharmacology & Therapeutics, Vol. 30, No. 1, 2009, pp. 61-70. doi:10.1111/j.1365-2036.2009.03995.x
[50] M. A. Loko, et al., “Impact of CART Exposure and Associated Lipodystrophy on Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients,” Journal of Viral Hepatitis, Vol. 18, 2010, pp. 307-314.
[51] P. Pérez-Matute, L. Pérez-Martínez, J. R. Blanco and J. A. Oteo, “Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes,” Current HIV Research, Vol. 9, No. 3, 2011, pp. 74-79. doi:10.2174/157016211795945278
[52] M. J. Fisher, C. M. Wyat, K. Gordon, et al., “Hepatitis C and the Risk of Kidney Disease and Mortality in Veterand with HIV,” Journal of Acquired Immune Deficiency Syndromes, Vol. 53, No. 2, 2010, pp. 222-226. doi:10.1097/QAI.0b013e3181b980d4
[53] H. Izzedine, D. Sene, P. Cacoub, et al., “Kidney Diseases in HIV/HCV Coinfected Patients,” AIDS, Vol. 23, No. 10, 2009, pp. 1219-1226. doi:10.1097/QAD.0b013e32832ac36a
[54] F. Collin, X. Duval, V. Le Moing, et al., “Ten Year Incidence and Risk Factor of Bone Fractures in a Cohort of Treated HIV-1 Infected Adults,” AIDS, Vol. 23, No. 8, 2009, pp. 1021-1024. doi:10.1097/QAD.0b013e3283292195
[55] C. H. Hinkin, S. A. Castellon, A. J. Levin, et al., “Neurocognition in Individuals Coinfected with HIV and Hepatitis C,” Journal of Addictive Diseases, Vol. 27, No. 2, 2008, pp. 11-17. doi:10.1300/J069v27n02_02
[56] H. A. Aronow, A. J. Weston, B. B. Pezeshki and T. S. Lazzarus, “Effects of Coinfection with HIV and Hepatitis C Virus on the Nervous System,” The AIDS Reader, Vol. 18, No. 1, 2008, pp. 43-48.
[57] P. Ancuta, A. Karnat, K. J. Kunstman, et al., “Microbial Translocation Is Associated with Increased Monocyte Activation and Dementia in AIDS Patient,” PLoS One, Vol. 3, No. 6, 2008, e2516. doi:10.1371/journal.pone.0002516
[58] J. Thorpe, S. Saeed, E. E. M. Moodie and M. B. Klein, “For the Canadian Co-Infection Cohort Study (CTN222). Antiretroviral Treatment Interruption Leads to Progression of Liver Fibrosis in HIV-hepatitis C Virus Co-Infection,” AIDS, Vol. 25, No. 7, 2011, pp. 967-975. doi:10.1097/QAD.0b013e3283455e4b
[59] M. López-Diéguez, M. L. Montes, J. F. Pascual-Pareja, et al, “The Natural History of Liver Cirrhosis in HIV-Hepatitis C Virus-Coinfected Patients,” AIDS, Vol. 25, No. 7, 2011, pp. 899-904. doi:10.1097/QAD.0b013e3283454174
[60] S. Dominguez, J. Ghoen, G. Peytavin, et al., “Impact of Hepatitis C and Liver Fibrosis on Antiretroviral Plasma Drug Concentrations in HIV-HCV Coinfected Patients The HEPADOSE Study,” Journal of Antimicrobial Chemotherapy, Vol. 65, No. 11, 2010, pp 2445-2449. doi:10.1093/jac/dkq320
[61] R. Bruno, S. Galastri, P. Sacchi, et al., “Gp120 Modulates the Biology of Human Hepatic Stellate Cells: A Link between HIV Infection and Liver Fibrogenesis,” Gut, Vol. 59, 2010, pp. 513-520. doi:10.1136/gut.2008.163287
[62] A. Kovacs, R. Karim, W. J. Mack, et al., “Activation of CD8 T cells Predicts Progression of HIV Infection in Women Coinfected with Hepatitis C Virus,” The Journal of Infectious Diseases, Vol. 201, No. 6, 2010, pp.823-834. doi:10.1086/650997
[63] V. D. Gonzalez, K. Falconer, K. G. Blom, et al., “High Levels of Chronic Immune Activation in the T-Cell Compartments of Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1 and on Highly Active Antiretroviral Therapy Are Reverted by Alpha Interferon and Ribavirin Treatment,” Journal of Virology, Vol. 83, No. 21, 2009, pp.11407-11411. doi:10.1128/JVI.01211-09
[64] G. Marchetti, P. Nasta, F. Bai, et al., “Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients,” PLoS One, Vol. 7, No. 2, 2012, e32028. www.europeanaidsclinicalsociety.org.
[65] Italian Ministry of Health, “Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic-Clinical Management of HIV-1 Infected Persons,” 2012. http://www.salute.gov.it/hiv/hiv.jsp
[66] G. Cariti, P. Nasta, G. Angarano, et al., “Sustained Virological Response (SVR) to Anti Hepatitis C (HCV) Therapy with Pegylated IFN Alpha (PegIFN) Plus Ribavirin (RBV) in Patient with HIV/HCV Coinfection,” ICAR Italian Conference on AIDS and retroviruses, 10-12 June, 2012, Naples, Italy oral communication OC 53.
[67] T. Reiberger, B. A. Payer, L. Kosi, et al. (For the Vienna HIV Coinfection Study Group), “Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4+ Cell Counts During and After Pegylated Interferon on Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients,” The Journal of Infectious Diseases, Vol. 203, No. 12, 2011, pp.1802-1806. doi:10.1093/infdis/jir194
[68] J. Berenguer, M. A. von Wichmann, C. Quereda, et al., “Effect of Accompanying Antiretroviral Drugs on Virological Response to Pegylated Interferon and Ribavirin in Patients Co-Infected with HIV and Hepatitis C Virus,” Journal of Antimicrobial Chemotherapy, Vol. 66, No. 12, 2011, pp. 2843-2849. doi:10.1093/jac/dkr362
[69] F. Bani-Sadr, L. Denoeud, P. Morand, et al., “Early Virologic Failure in HIV-Coinfected Hepatitis C Patients Treated with the Peginterferon-Ribavirin Combination: Does Abacavir Play a Role?” Journal of Acquired Immune Deficiency Syndromes, Vol. 45, No. 1, 2007, pp. 123-125. doi:10.1097/QAI.0b013e318040b2b6
[70] C. Solas, E. Pambrun, M. Winnock, et al. (For the ANRS CO-13 HEPAVIH Study Group), “Ribavirin and Abacavir Drug Interaction in HIV-HCV Coinfected Patients: Fact or Fiction? AIDS, Vol. 26, No. 17, 2012, pp. 2193-2199. doi:10.1097/QAD.0b013e32835763a4
[71] P. Nasta, F. Gatti, M. Puoti, et al., “Insulin Resistance Impairs Rapid Virologic Response in HIV/Hepatitis C Virus Coinfected Patients on Peginterferon-alfa-2a,” AIDS, Vol. 22, No. 7, 2008, pp. 857-861. doi:10.1097/QAD.0b013e3282fbd1c4
[72] P. Cacoub, F. Carrat, P. Bédossa, et al., “Insulin Resistance Impairs Sustained Virological Response Rate to Pegylated Interferon Plus Ribavirin in HIV-Hepatitis C Virus-Coinfected Patients: HOMAVIC-ANRS HC02 Study,” Antiviral Therapy, Vol. 14, 2009, pp. 839-845. doi:10.3851/IMP1298
[73] S. Naggie and M. S. Sulkowski, “Management of Patients Coinfected with HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals,” Gastroenterology, Vol. 142, No. 6, 2012, pp. 1324-1334. doi:10.1053/j.gastro.2012.02.012
[74] T. Kakuda, L. Leopold, S. Nijs, et al., “Pharmacoki Netic Interaction between Etravirine or Rilpivirine and Telaprevir in Healthy Volunteers: A Randomised, Two-Way Crossover Trial,” 13th International Workshop on Clinical Pharmacology of HIV Therapy, 16-18 April, 2012, Barcelona, Abstract O-18.
[75] E. Hulskotte, H. P. Feng, F. Xuan, et al., “Pharma Cokinetic Interaction between the HCV Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Lopinavir, and Darunavir,” 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March, 2012, Seattle, Abstract 771LB.